KAER Biotherapeutics has received a $300,000 Small Business Innovation Research (SBIR) grant from the National Heart Lung and Blood Institute of the National Institutes of Health for preclinical development of its SUPRAER aerosol platform for the treatment of surfactant-deficient premature infants with Respiratory Distress Syndrome (nRDS), the company said.
The SUPRAER platform has the ability to aerosolize viscous liquids, including biologics, generating aerosols with particle sizes from 1.5 to 5 μm. KAER has previously received SBIR grants for development of its SUPRAER technology for the treatment of acute respiratory distress syndrome (ARDS) in adults, including a $2 million grant announced in October 2018.
Read the KAER Biotherapeutics press release.
